Both companies will work to revolutionize cell culture media in biotech and the vaccine industry with animal-free, high-yield ...

Precision Medicine Group, a provider of next-generation drug development, CRO and commercialization services, has appointed Eric Hodgins as its Chief Information and Technology Officer, overseeing all ...

Bristol Myers Squibb’s Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...

Thermo Fisher Scientific Inc. has introduced the 5L DynaDrive Single-Use Bioreactor, expanding the company's portfolio of ...

Lifecore Biomedical Inc., a fully integrated contract development and manufacturing organization (CDMO), has appointed Thomas ...

Lonza will serve as a CMAC Translation to Industry Collaborator, reinforcing its commitment to advancing innovative ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Wyatt McDonnell of Infinimmune shares insight on human-first models and what the FDA's policy shift means for biotech R&D.

Novartis, an innovative medicines company, has announced plans to invest $23 billion over 5 years in U.S.-based ...

Vanessa Zann and Andrew Parker share insights on poorly soluble APIs, approaches for modified release formulation development, and navigating accelerated approval pathways.

Parexel, a clinical research organization (CRO), has appointed Charlotte Moser, MD, PhD, MBA as Chief Medical Officer.

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.